The tweet was deleted by the author.
But we saved everything 🙂.
NeoGenomics is making strides in the field of oncology by presenting their advanced services at the annual Targets25 conference.
Focused on accelerating oncology trials through cell therapy, ADCs, therapeutic development, spatial analysis, and genomics, NeoGenomics aims to enhance decision-making processes in cancer treatment.
Participants can visit booth 111 to learn more about NeoGenomics’ contributions to precision oncology and cancer therapeutics.
NeoGenomics' current initiatives in precision oncology align with its previous advancements, notably the development of RaDaR ST, unveiled at ESMO Congress 2025, which marked a significant step forward in medical diagnostics. The company's ongoing focus on spatial analysis and genomics is further underscored by the launch of Paletrra, a spatial proteomics solution designed to deepen tissue insights and enhance clinical outcomes.